Transarterial embolization of aldosterone producing adenoma of the adrenal gland – the DRAMA study

Not Applicable

Recruiting

• Conditions: E26.8; Other hyperaldosteronism

• Registration Number: DRKS00023816
• Lead Sponsor: Klinikum der Universität München, Campus Großhadern

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2022-09-08
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 19

Inclusion Criteria

Patients with a history of an arterial hypertension for more than 12 months, proven to have unilateral primary aldosteronism (PA) through adrenal venous sampling procedure
-Age: 18 to 75 years
-Patients not suitable for surgery or unwilling to undergo surgical resection
-Laboratory values like studyprotocol.

Exclusion Criteria

·Symptomatic peripheral arterial disease (PAD)
·History of obstructive sleep apnea
·Anatomical difficulties: High-grade aortic stenosis, access site impossibilities
·Renal insufficiency (eGFR < 30 ml/min)
·Severe contrast media intolerance
·Pregnancy

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Biochemical remission of the primary aldosteronism

Secondary Outcome Measures

Name	Time	Method
Biochemical remission (normal aldosterone to renin ratio or normal saline infusion test) 6 month following intervenition (according to PASO criteria )